4-(5-phenyl-1H-pyrazol-3-yl)benzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(5-phenyl-1H-pyrazol-3-yl)benzonitrile
• 英文别名: 4-(3-phenyl-1H-pyrazol-5-yl)benzonitrile
• 化学式: C₁₆H₁₁N₃
• 分子量: 245.283
• InChiKey: AMEDCWFRHRYVBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(3-phenylpropioloyl)benzonitrile 在 一水合肼 作用下， 以 水 为溶剂， 反应 3.0h， 生成 4-(5-phenyl-1H-pyrazol-3-yl)benzonitrile
  参考文献：
  名称：

  无铜纳米Pd催化连续酰基Sonogashira偶联-分子内环化反应在PEG-400 /水介质中一锅区域选择性合成取代的吡唑和异恶唑

  摘要：

  在环境友好的PEG-400 / H 2中原位生成的Pd-纳米颗粒（PdNPs）在区域选择性一锅合成3,5-di和3,4,5-三取代的吡唑和3,5-二取代的异恶唑的催化剂效力描述了一种O介质，它涉及（i）在PTC条件下无Cu的酰基-Sonogashira偶联（ASC）和（ii）分子内的ynone-amine环化。受控实验的结果支持两个连续的催化循环（ASC /环化）的操作，并通过一锅法通过与炔酮结合的钯实现互补/相反的区域选择性。而且，就地一锅法反应序列的第一个催化循环后回收的PdNPs已连续五次再次使用。此外，在进行上述研究之前，某些常见的Pd-N-杂环卡宾（Pd-NHC）配合物在水和有机物中催化相同的一锅两步反应顺序（无铜ASC /环化）的功效还优化了溶剂。还可以从水中的Pd-NHC上方原位生成PdNP，但由于它们的尺寸较大，因此无法重复使用。

  DOI：

  10.1039/c9cy01335k

文献信息

• [EN] NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES<br/>[FR] NOUVEAUX PYRAZOLES SUBSTITUÉS, 1,2,4-OXADIAZOLES, ET 1,3,4-OXADIAZOLES
  申请人：MERCK & CO INC

  公开号：WO2009146343A1

  公开（公告）日：2009-12-03

  The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted pyrazole derivatives, compositions, and therapeutic uses and processes for making such compounds.

  本发明涉及新型淀粉样蛋白结合化合物和测量这些化合物效果的方法，通过测量活体患者淀粉样斑块水平的变化。更具体地说，本发明涉及一种利用本发明化合物作为示踪剂在正电子发射断层扫描（PET）成像中研究活体大脑中淀粉样沉积以进行阿尔茨海默病诊断的方法。因此，本发明涉及将新型淀粉样蛋白结合化合物用作诊断的用途。该发明还涉及一种测量阿尔茨海默病治疗药物临床疗效的方法。具体而言，本发明涉及新型芳基或杂环芳基取代的吡唑衍生物、组成物和制备此类化合物的治疗用途和方法。
• Chemoselective synthesis of substituted pyrazoles through AgOTf-catalyzed cascade propargylic substitution–cyclization–aromatization
  作者：Su-Xia Xu、Lu Hao、Tao Wang、Zong-Cang Ding、Zhuang-Ping Zhan

  DOI：10.1039/c2ob27016a

  日期：——

  A cascade AgOTf-catalyzed chemoselective approach to 3,5/1,3-disubstitued pyrazoles from propargylic alcohols and para-tolylsulfonohydrazide has been developed. Good chemoselectivity is observed depending on the different substituents in the alkyne moiety of the propargylic alcohols, generating two different kinds of products through different aromatization mechanisms. The pyrazolo[5,1-a]isoquinoline skeleton can also be effectively constructed by this method through a cascade bicyclization process.

  开发了一种瀑布式AgOTf催化的化学选择性方法，能够从丙炔醇和对甲苯磺酰肼得到3,5/1,3二取代的吡唑。根据丙炔醇中炔烃部分的不同取代基，观察到良好的化学选择性，通过不同的芳构化机制生成两种不同类型的产物。该方法还可以通过级联双环化过程有效构建吡唑[5,1-a]异喹啉骨架。
• Sunlight-promoted Direct Irradiation of <i>N</i> -centred Anion: The Photocatalyst-free Synthesis of Pyrazoles in Water
  作者：Te Zhang、Yunge Meng、Jinye Lu、Yuting Yang、Gong-Qiang Li、Chunyin Zhu

  DOI：10.1002/adsc.201701200

  日期：2018.8.17

  been developed for the synthesis of pyrazole. Based on the analysis of UV‐Vis absorption of the substrate, the reaction was designed to avoid the use of external photocatalysis and proceeds via direct irradiation of N‐centred anion by sunlight. The key features of this reaction include operational simplicity, readily available reagents, and amenability to gram‐scale synthesis.

  已经开发了一种通过日光介导的α，β-不饱和azo的环合反应的实用方法，用于合成吡唑。基于对底物的UV-Vis吸收的分析，该反应被设计为避免使用外部光催化，并通过阳光直接照射N中心阴离子进行反应。该反应的关键特征包括操作简便，易于获得的试剂以及对克级合成的适应性。
• A Novel One-Pot Method for the Preparation of Pyrazoles by 1,3-Dipolar Cycloadditions of Diazo Compounds Generated in Situ
  作者：Varinder K. Aggarwal、Javier de Vicente、Roger V. Bonnert

  DOI：10.1021/jo0268409

  日期：2003.6.1

  procedure for the preparation of pyrazoles by 1,3-dipolar cycloaddition of diazo compounds generated in situ has been developed. Diazo compounds derived from aldehydes were reacted with terminal alkynes to furnish regioselectively 3,5-disubstituted pyrazoles. Furthermore, the reaction of N-vinylimidazole and diazo compounds derived from aldehydes gave exclusively 3-substituted pyrazoles in a one-pot process

  已经开发了一种方便的一锅法，该方法通过现场产生的重氮化合物的1,3-偶极环加成制备吡唑。使衍生自醛的重氮化合物与末端炔烃反应，以区域选择性地提供3,5-二取代的吡唑。此外，N-乙烯基咪唑和衍生自醛的重氮化合物的反应在一锅法中仅生成3-取代的吡唑。
• Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles
  申请人：Barrow James C.

  公开号：US20110081297A1

  公开（公告）日：2011-04-07

  The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted pyrazole derivatives, compositions, and therapeutic uses and processes for making such compounds.

  本发明涉及新型淀粉样蛋白结合化合物及测量这些化合物效果的方法，通过测量活体患者淀粉样斑块水平的变化来实现。更具体地说，本发明涉及使用本发明化合物作为追踪剂在正电子发射断层扫描（PET）成像中研究体内脑部淀粉样沉积，以诊断阿尔茨海默病。因此，本发明涉及将新型淀粉样蛋白结合化合物用作诊断工具。本发明还涉及测量阿尔茨海默病治疗药物的临床疗效的方法。具体而言，本发明涉及新型芳基或杂环芳基取代的吡唑衍生物、组成物以及制备这些化合物的治疗用途和过程。